6L8 Stock Chart & Stats
€41.20
€4.40(16.67%)
At close: 4:00 PM EDT
€41.20
€4.40(16.67%)
Day’s Range― - ―
52-Week Range€10.80 - €42.80
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
€2.93B
Enterprise Value€1.82K
Total Cash (Recent Filing)€101.62M
Total Debt (Recent Filing)€6.77M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 16, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding71,322,610
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€39.06Price Target Upside-5.21% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.05
Revenue Forecast (FY)€2.06M
Bulls Say, Bears Say
Bulls Say
Accelerated Pivotal Trial EnrollmentFaster-than-planned enrollment can shorten the path to definitive clinical evidence and regulatory decisions. It also signals operational execution and investigator interest, supporting Pulse’s ability to advance its lead cardiac platform.
Strong Clinical Efficacy And Safety SignalsDurable efficacy combined with a favorable safety signal could differentiate nsPFA from competing ablation approaches. If confirmed in pivotal studies, these outcomes may support adoption, regulatory progress and broader commercial potential.
Improved Liquidity And Low LeverageA well-capitalized, lightly levered balance sheet gives Pulse flexibility to fund pivotal trials and regulatory work without substantial debt burdens. The stronger liquidity position improves execution capacity during the commercialization buildout.
Bears Say
Minimal Commercial Revenue And Deep LossesThe limited revenue base shows that commercialization has not yet scaled enough to absorb development costs. Negative gross margins and large operating losses leave profitability dependent on successful adoption of future products.
Heavy Cash Burn And Financing DependencePersistent cash outflows require continued access to equity markets while clinical programs advance. Additional financing can dilute shareholders and create execution risk if market access or funding availability weakens before revenue becomes meaningful.
Regulatory Timeline Remains UncertainAccelerated enrollment does not eliminate the need for extended follow-up, so regulatory submission and approval timing remains exposed to data maturity. Delays could defer commercialization and prolong the period of high operating cash burn.
Pulse Biosciences News
6L8 FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was €10.80 and its highest was €42.80 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is €2.93B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 77 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -€0.245 earnings per share for the quarter, beating the consensus estimate of -€0.268 by €0.022.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Overvalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 71,322,610 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -€0.245 in its last earnings report, beating expectations of -€0.268. Following the earnings report the stock price went down -1.227%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in DE:6L8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€39.06 (-5.21% Downside)
€39.06 (-5.21% Downside)
Blogger Sentiment
Bullish
DE:6L8 Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
6L8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all DE:6L8 earnings summaries6L8 Stock 12 Month Forecast
Average Price Target
€39.06
▼(-5.21% Downside)